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Background: The purpose of this study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose–
positron emission tomography/computed tomography (FDG–PET/CT) during follow-up of patients with diffuse large
B-cell lymphoma (DLBCL) being in complete remission or unconfirmed complete remission after first-line therapy.
Patients and methods: DLBCL patients receiving FDG–PET/CT during follow-up were analyzed retrospectively.
Confirmatory biopsy was mandatory in cases of suspected disease recurrence.
Results: Seventy-five patients were analyzed and 23 (30%) had disease recurrence. The positive predictive value
(PPV) of FDG–PET/CT was 0.85. Patients >60 years [P = 0.036, hazard ratio (HR) = 3.82, 95% confidence interval (CI)
1.02–7.77] and patients with symptoms indicative of a relapse (P = 0.015; HR = 4.1; 95% CI 1.20–14.03) had
a significantly higher risk for relapse. A risk score on the basis of signs of relapse, age >60 years, or a combination of
these factors identified patients at high risk for recurrence (P = 0.041).
Conclusions: FDG–PET/CT detects recurrent DLBCL after first-line therapy with high PPV. However, it should not be
used routinely and if only in selected high-risk patients to reduce radiation burden and costs. On the basis of our
retrospective data, FDG–PET/CT during follow-up is indicated for patients <60 years with clinical signs of relapse and
in patients >60 years with and without clinical signs of relapse.
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introduction
The prognosis for patients with diffuse large B-cell lymphoma
(DLBCL) has improved after implementation of rituximab in
first-line chemotherapy, and a chance of cure also exists after
salvage therapy in case of relapse [1–3]. However, the
improvement seen from the use of rituximab in first-line
treatment may negatively impact on the chance of cure when
patients present with relapsed disease [4]. Therefore, efforts
have to be undertaken to develop optimized follow-up
procedures that detect relapse at an early or even preclinical
stage on the basis of the assumption that early detection of
relapse may allow onset of re-treatment at an early time point
and, eventually, improve survival. Current DLBCL guidelines
recommend radiological examinations at 6, 12 and 24 months
after end of treatment by computed tomography (CT) [5]. The
use of 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron
emission tomography (FDG–PET) has been established for the
initial staging and the assessment of treatment response during
and after completion of first-line therapy in lymphoma patients
[6], but only limited data are available regarding the impact
of FDG–PET for the follow-up of DLBCL patients who
achieved a complete remission (CR) or complete remission
unconfirmed (CRu) after initial therapy [7]. As of today, only
two prospective studies evaluating FDG–PET during follow-up
of lymphoma patients have been reported, with one study
focusing exclusively on patients with Hodgkin’s lymphoma
(HL) [8]. In the other study with a cohort of 183 patients with
aggressive non-Hodgkin’s lymphoma, the use of FDG–PET
led to earlier diagnosis of relapse compared with CT, and the
authors concluded that FDG–PET may be a valid tool for the
routine follow-up of lymphoma patients [9]. However, this
conclusion is debatable from our point of view because of rising
concerns over the increasing use of imaging modalities with
regard to patient safety and health care costs. We recently
identified the risk factors residual mass, advanced stage and
symptoms in HL patients, indicating a high-risk situation for
relapse, which may justify the use of FDG–PET for follow-up
[10]. In the present study, we identify DLBCL patients at high
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risk for relapse by retrospective analysis of our patient database.
The aim of this analysis was the development of a
risk-adapted strategy for the follow-up of DLBCL patients that
may help to reduce the radiation exposure of our patients
and health care costs.
patients and methods
patients
Patients with DLBCL in CR or CRu after first-line treatment who received
at least one FDG–PET combined with CT during their follow-up from
the beginning of 2002 until the end of 2008 were included in this study.
FDG–PET imaging data were acquired on a combined FDG–PET in-line
system (Discovery LS, RX or Discovery STE; GE Health Systems,
Milwaukee, WI), which permits the acquisition of co-registered CT and
FDG–PET (FDG–PET/CT) images in a single session.
All FDG–PET/CT scans were evaluated for the presence of abnormal
FDG uptake and residual disease. All image analysis was routinely carried
out by two dual board-certified nuclear radiology physicians in consensus.
CR in these patients had to be documented by one appropriate imaging
modality within 1 month after completion of first-line treatment (CT alone,
CT and FDG–PET, or FDG–PET/CT). All imaging was carried out at our
institution. CT scans were assessed for residual disease using the
International Workshop Criteria (IWC) [11].
A residual morphological mass after the end of treatment was defined as
a lesion that had regressed by >75% but was still >1.5 cm in its greatest axial
diameter (CRu). We further documented the initial stage of disease using
the Ann Arbor classification. Age, gender and signs of recurrence were
assessed and recorded by the referring physician before the follow-up FDG–
PET imaging was carried out. Signs of recurrence included B symptoms
or new suspicious masses. Relapse-free survival (RFS) was assessed in all
patients from the initial date of diagnosis until the date of recurrence as
documented by FDG–PET/CT. Histological confirmation was mandatory in
all patients with suspected recurrent disease. Our institutional ethics
committee had approved the study. Due to the retrospective nature of the
study, written informed consent of the patients was waived.
assessment of risk factors and patient classification
CT scans after the completion of first-line treatment were assessed for
residual morphological masses at the initial lymphoma sites using the IWC
as described above. Patients were assessed for advanced (IIIA–IVB) versus
early (IA–IIB) initial stage by Ann Arbor classification, extranodal disease
present versus absent, age and gender. Patient classification into the
symptomatic or asymptomatic group was done on the basis of reported
symptoms or referral notes by the treating physician.
statistical analysis
The primary goal was to provide estimates of survival for different values
of the variables provided. Kaplan–Meier plots are a graphical method to
represent the survival curves for each subgroup, using stratification.
Additionally, Cox proportional hazards regression was used to determine
whether the effect of the various factors (residual mass, extranodal disease,
initial stage, and presence of symptoms) was statistically significant,
through the use of a log-rank test. All analysis was carried out in the
R programming language, using the survival package [12].
results
patients and disease status
We collected data from patients with DLBCL who received one
or more follow-up FDG–PET/CT scans from 2002 to 2008 at
our institution. From 138 patients initially indexed, 63 patients
had to be excluded from analysis due to incomplete follow-up
data or administration of salvage therapy before FDG–PET/CT
was carried out. Overall, 75 patients with confirmed DLBCL
(45 male, 30 female; mean age 60; range from 23 to 90 years)
had sufficient follow-up data and were eligible for analysis. The
median follow-up was 16.5 months (range 6–93 months) for
the entire patient cohort. Patient characteristics are depicted in
Table 1. The patients had initially received CT alone (n = 19),
FDG–PET (n = 8), or FDG–PET/CT (n = 48) after completion
of first-line therapy. The median RFS was 57 months in the
entire patient cohort (range 7.7–93 months; Figure 1A).
Of the total number of 75 patients studied, twenty-seven
(36%) had a positive FDG–PET/CT during follow-up. Of all
75 patients, 40 (53%) received FDG–PET/CT due to clinical
signs indicating a relapse. From these 40 symptomatic patients,
23 (52.5%) had a positive FDG–PET and in 20 (50%), relapse
Table 1. Asymptomatic and symptomatic patient groups
n %
Asymptomatic patients (n = 35)
FDG–PET/CT
Positive 4 11.5
Negative 31 88.5
Recurrence
Yes 3 8.6
No 32 91.4
Morphological residual mass
Yes 14 40.0
No 21 60.0
Stage of disease
Early (IA–IIB) 23 65.7
Advanced (IIIA–IVB) 12 34.3
Extranodal disease
Yes 17 50.0
No 17 50.0
Advanced age (years)
<60 20 57.2
>60 15 42.8
Symptomatic patients (n = 40)
FDG–PET/CT
Positive 23 57.5
Negative 17 42.5
Recurrence
Yes 20 50.0
No 20 50.0
Morphological residual mass
Yes 32 80.0
No 8 20.0
Stage of disease
Early (IA–IIB) 17 42.5
Advanced (IIIA–IVB) 23 57.5
Extranodal disease
Yes 20 50.0
No 20 50.0
Advanced age (years)
<60 14 35.0
>60 26 65.0
FDG–PET/CT, 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission
tomography/computed tomography.
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Figure 1. Kaplan–Meier analysis of all patients [dashed line: 95% confidence interval (CI) (A)]. Univariate analysis for Ann Arbor classification (B),
residual disease after first-line therapy (C), extranodal disease (D), age (E) and clinical signs of relapse (F).
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was confirmed by biopsy. One patient had positive PET due
to secondary carcinoma of the lung and in two patients, the
biopsy showed no malignant cells. In the remaining group of 35
asymptomatic patients, 4 patients had a positive PET, and in
3 of them, relapse was confirmed by biopsy. A biopsy of one
patient showed no malignant cells. Overall, for all 75 patients,
FDG–PET/CT was able to detect relapses with a positive
predictive value (PPV) of 0.85.
In 21 patients (91%) from 23 relapsed patients sufficient
follow-up could be performed. The median RFS until the
second relapse was 16 months (range 1.4–99 months). In
relapsed patients, there was no significant difference in the RFS
until the second relapse for patients >60 years [n = 17 patients,
P = 0.83; hazard ratio (HR) = 0.88; 95% confidence interval
(CI) 0.20–3.61] compared with younger patients (n = 4) and
with clinical signs of relapse at time of the first relapse (n = 18
patients, P = 0.74; HR = 1.39; 95% CI 0.13–17.51) compared
with no clinical signs (n = 3).
risk factor assessment
We analyzed the initial stage at diagnosis by Ann Arbor
classification, residual disease after first-line therapy, extranodal
disease, age and clinical signs of relapse by univariate analysis.
Stage at diagnosis (P = 0.22; HR = 1.72; 95% CI 0.72–4.15),
residual disease (P = 0.31; HR = 0.6; 95% CI 0.22–1.63), and
extranodal disease (P = 0.25; HR = 1.64; 95% CI 0.70–3.85)
were not statistically significant predictors for relapse. Patients
>60 years (P = 0.036; HR = 2.82; 95% CI 1.02–7.77) and
patients with symptoms indicative of relapse (P = 0.015;
HR = 4.1; 95% CI 1.20–14.03) had a significantly shorter RFS
(Figure 1B–E).
A risk score including age >60 years and clinical signs of
relapse (zero to two risk factors) identified patients at high risk
for recurrence (P = 0.041). Only 1 patient from 20 patients
without symptoms and age <60 years had positive FDG–PET/
CT scans and a biopsy-proven relapse (Table 2). The median
RFS was not reached in patients without any of these risk
factors (Figure 2).
discussion
In the present study, we evaluated the impact of FDG–PET/CT
during the follow-up of patients with DLBCL who achieved
a CR or CRu after first-line treatment. Seventy-five patients
with CR or CRu after completion of first-line therapy were
eligible for the analysis. We evaluated symptomatic as well as
asymptomatic patients with regard to the risk factors advanced
stage of disease, residual disease after completion of therapy,
extranodal disease, patient age and clinical signs of relapse. We
intended to identify retrospectively risk factors for relapse that
may help to individualize the use of FDG–PET/CT during
follow-up and to reduce irradiation burden and treatment
costs. Symptoms as the reason for patient referral and patient
age >60 years were the most important risk factors. Both factors
were used in a risk score. The score was created with the
objective of assessing the risk of relapse for a patient and the
benefit of further imaging. Age >60 years or clinical symptoms
alone or the combination indicated high risk of relapse and,
therefore, justified intensified imaging. The PPV of 0.85 is in
accordance with other studies but also demonstrated again that
relapse has to be proven by biopsy [13]—may be especially
when rituximab-containing regimens were used [14].
Our results have to be interpreted in the context of the
current guidelines for the follow-up of DLBCL and the most
recently published prospective study of FDG–PET-based
surveillance by Zinzani et al. [5, 9]. In our study, patients <60
years with no clinical signs of relapse and no extranodal disease
have very low risk of relapse. Therefore, these patients may
not benefit from FDG–PET/CT scans during follow-up.
According to our analysis, the only indication for FDG–PET
in younger patients are clinical signs of relapse.
However, to finally implement these risk factors and their
consequences in regard to imaging-based surveillance,
treatment and survival for high- and low-risk patients,
a prospective trial has to be carried out. In this trial, patients
Figure 2. Kaplan–Meier analysis of the relapse-free survival of patients
with the risk factors clinical signs of relapse and age >60 years (solid line:
zero risk factors, dashed line: one risk factor, pointed line: two risk
factors), P < 0.05.
Table 2. Positive PET/CT and proven relapse by biopsy for all patients
and patients separated by age
Signs of
clinical
relapse
No signs
of clinical
relapse
All patients, n = 75 n (%), n = 40 n (%), n = 35
PET/CT positive 23 (57.5) 4 (11.5)
Biopsy positive 20 (50.0) 3 (8.6)
<60 years, n = 34 n = 14 n = 20
PET/CT positive 4 (28.6) 1 (5.0)
Biopsy positive 4 (28.6) 1 (5.0)
>60 years, n = 41 n = 26 n = 15
PET/CT positive 19 (73.1) 3 (20.0)
Biopsy positive 16 (61.5) 2 (13.3)
PET/CT, positron emission tomography–computed tomography.
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would need to be stratified for the risk factors described here
and then, PET/CT has to be tested versus CT alone at 6, 12
and 24 months after end of first-line treatment.
The study of Zinzani et al. indicates the use of FDG–PET/CT
for all patients with aggressive lymphoma. In contrast, on
the basis of the identification of this low-risk patient
group, 25% of the patients could be spared FDG–PET/CT
scans. The RFS decreased markedly in patients with a higher
risk score. Patients >60 years with clinical signs of relapse are
at high risk for relapse. In this situation, routine FDG–PET/CT
appears to be justified during follow-up. Nevertheless, the
impact on better survival due to earlier detection of disease
recurrence has yet to be proven in prospective randomized
studies. Therefore, at the moment, there is no indication in the
routine follow-up of patients with PET/CT. This relatively new
technique, if used, should be limited to selected patients that
are at high risk for recurrence [15].
The retrospective nature of this study and the relatively
small patient number are the most important limitations.
Additionally, FDG–PET/CT was not mandatory after first-line
treatment for the inclusion into the analysis because the revised
response criteria for malignant lymphoma were published in
2007 and our analysis included patients from 2002 to 2008.
FDG–PET/CT surveillance was not done at fix time points after
the end of the first-line treatment. The goal of our retrospective
analysis was rather to develop a rationale for the use of
FDG–PET/CT imaging in a well-defined patient population
with DLBCL after the completion of the first-line therapy.
In conclusion, FDG–PET/CT reliably detects recurrent
DLBCL after first-line therapy. FDG–PET/CT can be
considered during follow-up in high-risk patients for relapse
with age <60 years when clinical signs of relapse are present
and in patients with age >60 years regardless of clinical
symptoms of relapse. However, the routine use of PET/CT
during follow-up cannot be recommended until prospective
trials have demonstrated a survival benefit for patients followed
by PET/CT.
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